In the past week, CYTK stock has gone up by 3.71%, with a monthly decline of -0.60% and a quarterly surge of 6.40%. The volatility ratio for the week is 4.09%, and the volatility levels for the last 30 days are 3.85% for Cytokinetics Inc The simple moving average for the past 20 days is 0.62% for CYTK’s stock, with a -10.10% simple moving average for the past 200 days.
Is It Worth Investing in Cytokinetics Inc (NASDAQ: CYTK) Right Now?
The 36-month beta value for CYTK is at 0.78. Analysts have varying views on the stock, with 7 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CYTK is 113.74M, and currently, shorts hold a 16.01% of that float. The average trading volume for CYTK on September 18, 2024 was 1.39M shares.
CYTK) stock’s latest price update
Cytokinetics Inc (NASDAQ: CYTK)’s stock price has plunge by -1.04relation to previous closing price of 56.75. Nevertheless, the company has seen a 3.71% surge in its stock price over the last five trading sessions. benzinga.com reported 2024-09-09 that Monday, Cytokinetics, Incorporated CYTK announced that data from the Phase 1 study of CK-4021586 (CK-586) were presented in a poster session at the American College of Clinical Pharmacology Annual Meeting in Bethesda, MD.
Analysts’ Opinion of CYTK
Many brokerage firms have already submitted their reports for CYTK stocks, with Goldman repeating the rating for CYTK by listing it as a “Neutral.” The predicted price for CYTK in the upcoming period, according to Goldman is $60 based on the research report published on August 13, 2024 of the current year 2024.
UBS, on the other hand, stated in their research note that they expect to see CYTK reach a price target of $92, previously predicting the price at $61. The rating they have provided for CYTK stocks is “Neutral” according to the report published on January 24th, 2024.
Morgan Stanley gave a rating of “Equal-Weight” to CYTK, setting the target price at $90 in the report published on January 05th of the current year.
CYTK Trading at -0.11% from the 50-Day Moving Average
After a stumble in the market that brought CYTK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.06% of loss for the given period.
Volatility was left at 3.85%, however, over the last 30 days, the volatility rate increased by 4.09%, as shares sank -0.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.90% lower at present.
During the last 5 trading sessions, CYTK rose by +3.71%, which changed the moving average for the period of 200-days by +74.74% in comparison to the 20-day moving average, which settled at $55.80. In addition, Cytokinetics Inc saw -32.73% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CYTK starting from Malik Fady Ibraham, who sale 7,300 shares at the price of $56.77 back on Sep 17 ’24. After this action, Malik Fady Ibraham now owns 120,920 shares of Cytokinetics Inc, valued at $414,401 using the latest closing price.
Blum Robert I, the President & CEO of Cytokinetics Inc, sale 5,000 shares at $55.99 during a trade that took place back on Sep 16 ’24, which means that Blum Robert I is holding 397,456 shares at $279,950 based on the most recent closing price.
Stock Fundamentals for CYTK
Current profitability levels for the company are sitting at:
- -161.48 for the present operating margin
- -28.87 for the gross margin
The net margin for Cytokinetics Inc stands at -173.99. The total capital return value is set at -0.36.
Based on Cytokinetics Inc (CYTK), the company’s capital structure generated 0.86 points at debt to capital in total, while cash flow to debt ratio is standing at -0.59. The debt to equity ratio resting at 6.2. The interest coverage ratio of the stock is -6.96.
Currently, EBITDA for the company is -484.31 million with net debt to EBITDA at -1.23. When we switch over and look at the enterprise to sales, we see a ratio of 2299.76. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.39.
Conclusion
In conclusion, Cytokinetics Inc (CYTK) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
